1. Preparing the (200 mg Ondexxya®) vials 2. Reconstituting the lyophilisate in the vials In-use stability after reconstitution
Publication Update: Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors - NOAC Education NOAC Education
Andexanet Alfa and its Clinical Application – touchCARDIO
NCPE Plain English Summary
EMA-Geschäftsbericht 2019 veröffentlicht: Nach dem Umzug endlich wieder nach vorne blicken
EX-99.1
Ondexxya, INN-andexanet alfa
Andexanet alfa | New Drug Approvals
Public Summary SwissPAR - Ondexxya® (active substance: andexanet alfa)
Evidence for Andexanet Alpha in Reversing Intracerebral Hemorrhage due to Factor Xa Inhibitors? | Stroke
EMA approves eight meds for market - European Biotechnology
Andexanet alfa for the reversal of factor Xa inhibitors
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers - ScienceDirect
Public Summary SwissPAR - Ondexxya® (Wirkstoff: Andexanet alfa)
Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke | SpringerLink
Press release CHMP Ondexxya
EMA - Abstract 22: Agreement Between Capillary And Venous Lactate In The ED | EM:RAP
Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants | Journal of the American College of Cardiology
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) Online Satın Alın - Fiyat & Maliyetler | Everyone.org
Andexanet Alfa and its Clinical Application – touchCARDIO
Primer antídoto para rivaroxaban y apixaban: con condiciones. | El Blog de Farmacología Clínica
Ondexxya, INN-andexanet alfa
